Oppenheimer Reiterates an 'Outperform' on Curis (CRIS); Approval Ahead Of Schedule
Tweet
Share
E-mailGet Alerts CRIS Hot Sheet
Price: $1.78 -1.11%
Rating Summary:
17 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 6 | Down: 13 | New: 26
Rating Summary:
17 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 6 | Down: 13 | New: 26
Join SI Premium – FREE
Oppenheimer reiterates an 'Outperform' on Curis (NASDAQ: CRIS) price target raised from $6.00 to $7.50.
Oppenheimer analyst says, "Curis and partner Genentech/Roche (OTC: RHHBY)(Not Rated) announced the approval of Erivedge (vismodegib) for the treatment of Advanced Basal Cell Carcinoma (BCC) and pricing of $7,500/month. The approval is ahead of the March 8th PDUFA date. We believe that the market's negative reaction may be due to the recent runup in the stock (buy on the rumor, sell on the news) and/or the blackbox warning label regarding pregnancy. In our view the birth-defect risk is expected, based on the drug's mechanism of action."
For an analyst ratings summary and ratings history on Curis click here. For more ratings news on Curis click here.
Shares of Curis closed at $4.75 yesterday.
Oppenheimer analyst says, "Curis and partner Genentech/Roche (OTC: RHHBY)(Not Rated) announced the approval of Erivedge (vismodegib) for the treatment of Advanced Basal Cell Carcinoma (BCC) and pricing of $7,500/month. The approval is ahead of the March 8th PDUFA date. We believe that the market's negative reaction may be due to the recent runup in the stock (buy on the rumor, sell on the news) and/or the blackbox warning label regarding pregnancy. In our view the birth-defect risk is expected, based on the drug's mechanism of action."
For an analyst ratings summary and ratings history on Curis click here. For more ratings news on Curis click here.
Shares of Curis closed at $4.75 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gartner (IT) PT Lowered to $206 at BMO Capital, adjusting estimates
- Marvell (MRVL) PT Raised to $225 at TD Cowen
- TD Cowen Reiterates Buy Rating on NVIDIA (NVDA), 'unlikely to move significantly on earnings'
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
